Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

• Main Authors: Arjun Bhadhuri (Author), Daniel Dröschel (Author), Mike Guldimann (Author), Claudia Jetschgo (Author), Judit Banhazi (Author), Matthias Schwenkglenks (Author), C. Simone Sutherland (Author)
• Format: Book
• Published: BMC, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Objective We aimed to evaluate the cost-effectiveness of voretigene neparvovec (VN) compared with standard of care (SoC) for patients with inherited retinal disease (IRD) caused by a biallelic RPE65-mutation. VN is a live, non-replicating adeno-associated virus serotype 2 (AAV2). SoC is bes...